Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted signal transduction therapies in myeloid malignancies.

Current oncology reports - 1 Nov 2010

Scott Emma, Hexner Elizabeth, Perl Alexander, Carroll Martin

Abstract excerpt

The myeloid malignancies include the myeloproliferative neoplasms (MPN) including chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). A growing body of evidence documents that these diseases are caused by genetic mutations that constitutively activate tyrosine kinases. They include the BCR/ABL in CML, the V617F JAK2 in Philadelphia chromosome-negative MPN, and the Flt3 ITD and TKD mutations in AML....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Clinical Trials, Phase III as Topic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Leukemia, Myeloid, Acute

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 20809224
DOI: 10.1007/s11912-010-0126-z

Genes

JAK2
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted signal transduction therapies in myeloid malignancies.PMID 20809224Read ↗

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.Semantic proximity Read ↗

Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.Semantic proximity Read ↗

Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality.Semantic proximity Read ↗

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Semantic proximity Read ↗

Kinase drug discovery approaches in chronic myeloproliferative disorders.Semantic proximity Read ↗

Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

JAK2 in myeloproliferative disorders is not just another kinase.Semantic proximity Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.Semantic proximity Read ↗

Oncogenes in myeloproliferative disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.